

1 **A Paradoxical Screening Serological Assay for the Diagnosis of Whipple's Disease**
2 **(infection with *Tropheryma whipplei*)**

3
4 K.C. Liew^{a,b,d,#}, Chelsea Nguyen^b, Nilakshi T Waidyatillake^{c,e}, John Stenos^b, Aaron Walton^{b,d},
5 Eugene Athan^{b,c,d}, Owen Harris^{a,c,d}, and Stephen Graves^{b,*}

6
7 ^aDepartment of Microbiology, Australian Clinical Labs, Geelong Laboratory, Geelong 3220,
8 VIC, Australia.

9 ^bAustralian Rickettsial Reference Laboratory, University Hospital Geelong, Geelong 3220, VIC,
10 Australia.

11 ^cDeakin University, School of Medicine, Geelong 3220, VIC, Australia.

12 ^dBarwon Health, University Hospital Geelong 3220, VIC, Australia.

13 ^eAllergy and Lung Health Unit, Centre for Epidemiology and Bio statistics, Melbourne School of
14 Population and Global Health, The University of Melbourne, VIC, Australia.

15
16 Running Head: Whipple's Disease Screening Serological Assay

17
18 #Address correspondence to K. C. Liew, lwkwel@yahoo.com.au.

19 *Alternative Corresponding author: Prof Stephen Graves, graves.rickettsia@gmail.com

20 Author order was determined based on seniority and contribution to this work.

21 This is contribution from the Australian Rickettsial Reference Laboratory in evaluating the
22 screening serological assay for the diagnosis of Whipple's Disease.

23

24

25 **ABSTRACT**

26

27 Whipple's disease (WD) is a rare infection due to *Tropheryma whipplei*. Following *in-vitro*
28 cultivation of *T. whipplei*, an indirect-immunofluorescence serological assay (IFA) was
29 developed. We tested the hypothesis that this assay could be used to either identify WD patients,
30 or rule out WD, in patients in whom the diagnosis is being considered, based on the antibody
31 titers of their IgM and IgG antibody responses. In this small study fourteen WD patients and 22
32 healthy volunteers' sera were obtained from across Australia. All specimens were coded and de-
33 identified before testing. A patient with an IgG antibody titer of $\leq 1:16$ may have WD [sensitivity
34 57% (8/14) and specificity close to 100% (22/22)]. High IgM antibody titers ($\geq 1:256$) were more
35 common in WD patients [sensitivity 50% (7/14) and specificity 86% (19/22)] than in controls.
36 The area under Receiver-Operator-Characteristic curve for IgG in the IFA assay was 0.84 (95%
37 CI 0.69-1.00). At an IgG antibody titer of $\leq 1:16$ the Youden's index was 0.57. WD patients'
38 under-produce IgG antibody to *T.whipplei* but are more likely to over-produce IgM antibodies.
39 This screening IFA serological assay may be clinically useful in detecting those with a possible
40 diagnosis of WD. Patients with an IgG antibody titer of $\leq 1:16$ and an IgM antibody titer of
41 $\geq 1:256$ may have WD and should proceed to a tissue biopsy and PCR for confirmation. Further
42 validation of this assay, by increasing the sample size, by testing it in patients with non-WD
43 disease and trialing in other countries should be undertaken.

44

45

(247 words)

46

47 **INTRODUCTION**

48

49 Whipple's disease (WD) is a rare infection with *Tropheryma whipplei* with an estimated
50 prevalence of 1.1 to 9.8 cases per million inhabitants and an annual incidence of 1 to 6 per 10
51 million inhabitants (1-3). In small case series from Germany, Spain and north-western Italy, the
52 maximum incidence of WD was in persons between 40-60 years of age, of whom 72-96% were
53 middle-aged Caucasian men (2-7). In contrast to these findings, a large retrospective population-
54 based study carried out between 2012 and 2017 in the United States (US) found that men and
55 women were affected at similar rates and that WD was more common in people aged greater
56 than 65 years (3).

57

58 The clinical spectrum of WD is wide (1,5,8,9). In classical WD, infection with *T. whipplei*
59 probably occurs years before the first clinical manifestations, which are most often chronic
60 diarrhea or migratory arthralgia (1,9). In localized disease, *T. whipplei* can infect the joints,
61 bones, brain, heart, skin, eyes, lymph nodes, lung and/or kidney (1,8,9). Other associated
62 syndromes include acute, self-limited gastroenteritis and pneumonia (1,9). A broad spectrum of
63 clinical severity has been observed, ranging from asymptomatic carriage (5,8) to organ failure
64 and death. Fatal outcome is associated with delayed diagnosis as well as misdiagnosis as an
65 autoimmune/inflammatory disorder with consequent immunosuppressive treatment (9).

66

67 It has been observed that patients with confirmed WD frequently have reduced or undetectable *T.*
68 *whipplei*-specific IgG antibody levels. We have hypothesized that WD patients may not be able
69 to mount an adequate IgG antibody response. Persons who do not go on to develop clinical WD,

70 by contrast, appear to mount a strong IgG antibody response when exposed to *T. whipplei*. While
71 healthy individuals not yet exposed to the bacterium (mostly children and young adults) are
72 necessarily IgG seronegative, they respond normally when exposed. The aim of this study was to
73 compare the sera of patients with confirmed WD to healthy individuals without WD. We set out
74 to evaluate the diagnostic utility of a *T. whipplei* screening IFA serology assay as a tool to
75 distinguish patients with WD from those without.

76
77

78 **PATIENTS, MATERIALS AND METHODS**

79

80 **Study Design**

81 A small case comparative study of *T. whipplei* IFA was conducted from November 2019 until
82 May 2020 at the Australian Rickettsial Reference Laboratory (ARRL), Geelong, Victoria,
83 Australia, according to the *National Statement on Ethical Conduct in Human Research (2007)*
84 guideline (Barwon Health ethics reference number: 19/135). Written informed consent was
85 obtained from WD patients and healthy controls. All sera tested in this study were de-identified.

86

87 Participant selection criteria included English language proficiency and age > 18 years.
88 Pregnancy, active malignancy, primary immunodeficiency and HIV with CD4 lymphocyte count
89 < 200 were grounds for exclusion. Subjects were considered WD cases if they displayed
90 consistent symptoms with supportive diagnostic test results, such as positive periodic acid-Schiff
91 (PAS) staining, *T. whipplei*-specific immunohistochemistry staining or *T. whipplei* PCR of a
92 biopsy specimen (10-12).

93

94 **Sample size**

95 We employed a convenience sampling strategy, given the limited number of WD patients in
96 Australia. In total, we recruited 36 participants. Fourteen patients with confirmed WD were
97 recruited from across Australia. Twenty-two healthy controls were recruited locally.

98

99 **Diagnostic techniques**

100

101 **Culture and IFA slide preparation**

102 A French strain of *T. whipplei* was cultivated in liquid axenic medium at 35°C for several weeks
103 (13). Resultant *T. whipplei* cells were pelleted and resuspended in phosphate buffered saline
104 (PBS). To optimize antigen concentrations for the final immunofluorescence assay (IFA), slides
105 were prepared using doubling dilutions of *T. whipplei* antigen and subjected to sandwich IFA
106 after incubation with a strongly reacting serum sample. Antigen aliquots were stored at -70°C
107 until required. When thawed, they were spotted onto clean 3 x 10 well glass slides. After air
108 drying, antigens were fixed with acetone for 5 minutes. Slides could then be stored at -70°C for
109 later use.

110

111 **Indirect-immunofluorescence assay (IFA)**

112 All sera from the WD patients and controls were tested by our in-house *T. whipplei* IFA. Known
113 reactive and non-reactive sera were tested on the same slide as the assay samples. Initial 1:8
114 dilutions of test and control sera were prepared using 2% casein PBS buffer. Serial doubling
115 dilutions from 1:8 to 1:4096 were prepared and tested by IFA. Dilute sera were spotted in
116 duplicate onto pre-prepared *T. whipplei* slides. Slides were incubated for 30 minutes under
117 humid conditions at 35°C and thereafter washed for 5 minutes in a 1:10 dilution of PBS and

118 allowed to dry. Fluorescein-conjugated goat-anti-human antibodies, [1:100 anti-human IgA
119 (KPL, Cat # 02-10-01), 1:100 anti-human IgM (KPL, Cat # 02-10-03) and 1:100 anti-human IgG
120 (KPL, Cat # 02-10-02)] were applied, and slides were incubated, washed and dried as above.
121 Fluorescence mounting fluid (Dako North America, Inc., USA) and a coverslip were applied.
122 Microscopic evaluations of the IFA were carried out under 400x magnification using an LED
123 Leica DMLS fluorescence microscope. The assay was repeated in duplicate for all sera.
124 Antibody titers for IgM, IgG and IgA were defined as the highest serum dilution giving strong
125 immunofluorescence.

126

127 **Sample collection**

128

129 Of the 14 WD cases, eleven had sera already in storage. The remaining three cases had serum
130 sample collection organized through their local doctors and pathology services. Healthy control
131 sera were collected by the study doctor (KCL). Data such as gender, age range, IgM, IgG and
132 IgA antibody titers to *T. whipplei* were recorded.

133

134 **Statistical analysis**

135 Statistical comparisons of groups, by 2-sided Fisher exact test was done on the quantitative data.
136 Sensitivity was defined as the proportion of WD patients correctly identified at a particular
137 antibody cutoff (14). The definition for specificity was the proportion of healthy controls
138 correctly identified as not having WD (15). The clinical accuracies of the *T. whipplei* IFA assays
139 were examined by using Receiver-Operator-Characteristic (ROC) plots with GraphPad Prism
140 version 8.0.2 (GraphPad Software, San Diego, CA, USA) (15). ROC area under the curve (AUC)
141 were calculated as the fraction “correctly identified to be positive” and the fraction “falsely

142 identified to be positive” determined according to researcher cutoff values for positive results
143 (15). The Youden index, a function of sensitivity and specificity, was a commonly used measure
144 of overall diagnostic effectiveness (16). This index ranged between 0 and 1, with values close to
145 1 indicating that the biomarker's effectiveness was relatively large, and values close to 0
146 indicating limited effectiveness (16). Likelihood determined the probability that a test result was
147 correct to the probability that the test result was incorrect (17).

148

149

150 **RESULTS**

151

152

153 **Case presentations and demographics**

154 The clinical presentations of the fourteen WD cases included in this study were varied. Half of
155 them had infective endocarditis; three subjects displayed central nervous system manifestations;
156 two had classic WD with intestinal malabsorption, and two had joint manifestations. All but one
157 case subject was male. Ages ranged from 36-85 years old, with a mean age of 59 (Table 1).

158

159 **Healthy controls' demographics**

160 Of the healthy controls, 6 of 22 (27%) were males with ages ranging from 20-75 years old (Table
161 2). Mean age of healthy controls was forty.

162

163 **IgG IFA**

164 WD patients (n=14) (Table 1) were less able to produce IgG antibodies to *T. whipplei* compared
165 with healthy controls (n=22) (Table 2) and shown by comparison in Table 3. This difference was
166 significant when comparing antibody titers at 1:16, 1: 32, 1:64; 1:128 and 1:256 dilutions (p
167 $<.05$).

168

169 At a serum dilution of 1:256, 15 of 22 (68%) healthy controls had IgG to *T. whipplei* compared
170 to only 2 of 14 (14%) WD cases ($p < 0.05$). With an IgG titer cutoff set at less than 1:256,
171 sensitivity and specificity of the IFA were 86% (95% CI 57-98%) and 68% (95% CI 45-86%)
172 respectively (Table 3).

173

174 All twenty-two healthy controls had detectable *T. whipplei* IgG at a serum dilution of 1:32,
175 compared with 6 of 14 (43%) WD cases ($p < 0.05$). While the sensitivity was only 57% at this
176 cutoff, specificity approached 100% (95% CI 85-100%). The area under the Receiver-Operator-
177 Characteristic curve for IgG was 0.84 (95% CI 0.69 – 1.00). At an IgG antibody titer cutoff <
178 1:32, the Youden's index was 0.57 (Figure 1).

179

180 **IgM IFA**

181

182 IgM antibodies to *T. whipplei* were detected in a higher proportion of WD cases than in healthy
183 controls ($p = 0.03$) (Table 4). With the titer cutoff set at 1:256, sensitivity and specificity for the
184 IgM IFA were 50% (95% CI 23-77%) and 86% (95% CI 65-97%) respectively. The area under
185 the ROC curve was 0.65 (95% CI 0.45- 0.86). Using this cutoff, Youden's index was 0.36
186 (Figure 2).

187

188 **IgA IFA**

189

190 No difference in *T. whipplei* IgA IFA antibody titers was observed between WD cases and
191 controls ($p = 1.0$). This antibody isotype does not discriminate between these two groups.

192

193

194 **DISCUSSION**

195

196 Although small our study appears to confirm the hypothesis that patients with WD under-
197 produce IgG antibody compared with healthy controls. This finding is consistent with previous
198 reports (18,19,22,24). Using ROC analysis, we were able to optimize antibody titer cutoffs and
199 arrive at a potentially useful screening diagnostic assay diagnostically. In patients old enough to
200 have been naturally exposed to *T. whipplei*, those with IgG antibody titers lower than 1:32 are
201 likely to have WD (specificity ~100%). In a previous French study, when the cutoff titer was set
202 at 1:100, IgG did not discriminate between subjects with and without WD (20). The discrepancy
203 between this result and ours might be explained by the different antibody cutoff titers used as
204 well as possible technical differences in the assays. While these results will need to be replicated
205 and more work needs to be done to determine age- and region-specific rates of WD IgG
206 seropositivity in the general population, we believe that, at least in an Australian context, this
207 assay has the potential to be useful for excluding the diagnosis of WD.

208

209 Moreover, while it was less clearly discriminatory than IgG, we also observed differing rates of
210 *T. whipplei* IgM positivity between WD cases and controls. Of note, the pattern of IgM
211 positivity was opposite to that seen in the case of IgG, with IgM detectable at high titer in a
212 significantly *higher* proportion of cases than controls. This finding could suggest a defect in B
213 cell isotype switching from IgM to IgG in WD patients. In our study, only a single WD case
214 (subject #13) appears to have switched from IgM (low titer 1:128) to IgG (high titer 1:4096)
215 (Table1). This subject's serum sample was collected just days after he underwent open heart

216 surgery, and we speculate that blood transfusions he received might have influenced his antibody
217 readings by detecting donor antibodies as his own.

218

219 In contrast to prior studies, we did not find *T. whipplei* IgA to be useful in discriminating
220 between patients with and without WD (21,22). We did not detect serum IgA in any subject
221 from either the case or control group. Secretory IgA in intestinal mucus might correlate to recent
222 exposure to *T. whipplei*, but it would be challenging to measure routinely.

223

224 The usual serological response to a primary bacterial or viral infection would involve a
225 conversion of IgM to IgG isotype modulated by T cell cytokines. Seroconversion or a four-fold
226 rise in antibody titer would be expected after about a 10-14-day interval (23). Our serological
227 findings in WD patients were contrary to this. This may be due to a specific genetic
228 predisposition to WD that is associated with human leucocyte antigen (HLA) alleles DRB1*13
229 and DQB1*06, which may disrupt optimum antigen presentation (25). IL16 gene polymorphisms
230 and other polymorphisms polarize cytokine production towards T-helper-2 (Th2)-cell activity
231 (26-27). This specific genetic predisposition probably explains the inability of switching IgM to
232 IgG antibody isotype. In addition, there appears to be a decrease in Th1 and Th17 activity, poor
233 synthesis of TGF-beta 1 and excess synthesis of IL-10 (19,28-30). Furthermore, bacterial
234 virulence and immunogenicity may be modulated by a bacterial glycoprotein inter-cellular
235 biofilm (18,22,24). This biofilm can prevent the immune system from recognizing the bacterium
236 and impair the switch from IgM to IgG antibody isotype by the patient, a biological mechanism
237 that changes a B cell's production of antibody from one class to another (18,22,24).

238

239 22/22 (100%) of the healthy control group had IgG to *T. whipplei* detected by IFA at a 1:32
240 serum dilution, or higher, suggesting that the microbe may be widespread in the Australian
241 environment. *T. whipplei* has been detected in 37-66% of waste from sewage plants (4,30-33)
242 and in stool samples of 48% children in Laos (35), 12-26% of sewage plant workers (32) and 1-
243 11% of healthy individuals in France (36). The bacterium is also viable in human feces and
244 saliva (12), supporting the notion of human colonization, probably through fecal-oral
245 transmission. Further work with larger sample populations will be required to fully characterize
246 rates of exposure to *T. whipplei* in relevant communities.

247
248 There are several limitations to this study. Only a single strain of *T. whipplei* was used to
249 prepare target antigens for the IFA. Thus, if there are strain-specific differences in antibody
250 affinities, it might have affected our results. Another potential confounder is nonspecific
251 antibody reactivity, especially with antibodies of the IgM isotype. To address this concern, we
252 set the cutoff for IgM reactivity at the relatively high titer of 1:256. Nevertheless, the potential
253 for nonspecific IgM cross-reactivity remains and must be considered in this study's
254 interpretation. Finally, the absent/low antibody responses we observed in some healthy controls
255 complicate the reliance of absent *T. whipplei* IgG responses as a marker for active WD. We
256 may presume that absence of antibodies in healthy individuals reflects lack of exposure, however
257 the age-specific frequencies of such patterns of serological response remain to be determined.

258
259 Despite these limitations, our study demonstrates that *T. whipplei* screening serology is a
260 promising diagnostic modality for this uncommon disease. Given the rarity of WD and the
261 invasive nature of existing diagnostic tests, an inexpensive, non-invasive serological assay with

262 sufficient sensitivity to reliably exclude the diagnosis will be a worthwhile addition to the
263 diagnostic armamentarium.

264 (2,311 words)

265

266

267 **Acknowledgments.** The authors thank Prof Didier Raoult and Dr Pierre-Edouard Fournier for the
268 French *Tropheryma whipplei* isolate.

269

270 They also thank all the patients who were involved in this study and the healthy volunteers from
271 Geelong for assisting with the studies.

272

273 Associate Prof Denis Spelman, Associate Prof James Branley, Dr Ashley Watson, Dr Brian
274 Chong, Dr Callum Maggs, Dr Cameron Jeremiah, Dr Carly Hughes, Dr Caroline Bartolo, Dr
275 Christopher Swan, Dr David Andresen, Dr David Foley, Dr David Sheffield, Dr David Sowden,
276 Dr Freya Langham, Dr Hao Yu, Dr Harsha Sheorey, Dr Gabrielle O' Kane, Dr Hui Yi Ng, Dr
277 Jenny Robson, Dr Katy Lai, Dr Lucy Crawford, Dr Mike Catton, Dr Renjy Nelson, Dr Rob
278 Pickles, Dr Tristan Gibbs, Dr Sandra Jones, Dr Smathi Chong, Dr Su Ann Ho, and Dr Zaal
279 Meher-Homji are thanked for referring their patients to this study.

280

281 **Funding.** This study was investigators-initiated, supported by the Australian Rickettsial
282 Reference Laboratory.

283

284 ***Conflicts of interest.*** All authors: No reported conflicts of interest. All authors have submitted
285 the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors
286 consider relevant to the content of the manuscript have been disclosed.

287

288 **REFERENCES**

- 289
- 290 1. Schneider T, Moos V, Loddenkemper C, et al. Whipple's disease: new aspects of
291 pathogenesis and treatment. *Lancet Infect Dis*. 2008;8(3):179-190.
292 [https://doi:10.1016/S1473-3099\(08\)70042-2](https://doi.org/10.1016/S1473-3099(08)70042-2)
293
- 294 2. von Herbay A, Otto HF, Stolte M, et al. Epidemiology of Whipple's disease in Germany.
295 Analysis of 110 patients diagnosed in 1965-95. *Scand J Gastroenterol*. 1997;32(1):52-57.
296 [https://doi:10.3109/00365529709025063](https://doi.org/10.3109/00365529709025063)
297
- 298 3. Elchert JA, Mansoor E, Abou-Saleh M, Cooper GS. Epidemiology of Whipple's Disease
299 in the USA Between 2012 and 2017: A Population-Based National Study. *Dig Dis Sci*.
300 2019;64(5):1305-1311. [https://doi:10.1007/s10620-018-5393-9](https://doi.org/10.1007/s10620-018-5393-9)
301
- 302 4. Dutly F, Altwegg M. Whipple's disease and "*Tropheryma whippelii*". *Clin Microbiol*
303 *Rev*. 2001;14(3):561-583. [https://doi:10.1128/CMR.14.3.561-583.2001](https://doi.org/10.1128/CMR.14.3.561-583.2001)
304
- 305 5. Lagier JC, Lepidi H, Raoult D, et al. Systemic *Tropheryma whippelii*: clinical
306 presentation of 142 patients with infections diagnosed or confirmed in a reference center.
307 *Medicine (Baltimore)*. 2010; 89(5): 337–345. [https://doi:](https://doi.org/10.1097/MD.0b013e3181f204a8)
308 10.1097/MD.0b013e3181f204a8. PMID: 20827111.
309

- 310 6. Biagi F, Balduzzi D, Delvino P, Schiepatti A, Klersy C, Corazza GR. Prevalence of
311 Whipple's disease in north-western Italy. *Eur J Clin Microbiol Infect Dis*.
312 2015;34(7):1347-1348. [https://doi:10.1007/s10096-015-2357-2](https://doi.org/10.1007/s10096-015-2357-2)
- 313
314 7. Ojeda E, Cosme A, Lapaza J, Torrado J, Arruabarrena I, Alzate L. Whipple's disease in
315 Spain: a clinical review of 91 patients diagnosed between 1947 and 2001. *Rev Esp*
316 *Enferm Dig*. 2010;102(2):108-123. [https://doi:10.4321/s1130-01082010000200006](https://doi.org/10.4321/s1130-01082010000200006)
- 317
- 318 8. Günther U, Moos V, Offenmüller G, et al. Gastrointestinal diagnosis of classical
319 Whipple disease: clinical, endoscopic, and histopathologic features in 191
320 patients. *Medicine (Baltimore)*. 2015;94(15): e714.
321 [https://doi:10.1097/MD.0000000000000714](https://doi.org/10.1097/MD.0000000000000714)
- 322
- 323 9. Marth T, Schneider S. Whipple's disease. In: *Principles and practice of infectious*
324 *disease*, 8th edn. Mandell G, Bennett J, Dolin R, eds. Philadelphia: Elsevier, 2015;
325 2418–2425.
- 326
- 327 10. Fenollar F, Puéchal X, Raoult D. Whipple's disease. *N Engl J Med*. 2007;356(1):55-66.
328 [https://doi:10.1056/NEJMra062477](https://doi.org/10.1056/NEJMra062477)
- 329
- 330 11. Lepidi H, Fenollar F, Gerolami R, et al. Whipple's disease: immunospecific and
331 quantitative immunohistochemical study of intestinal biopsy specimens. *Hum Pathol*.
332 2003;34(6):589-596. [https://doi:10.1016/s0046-8177\(03\)00126-6](https://doi.org/10.1016/s0046-8177(03)00126-6)
- 333

- 334 12. Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D. Value of *Tropheryma whippelii*
335 quantitative polymerase chain reaction assay for the diagnosis of Whipple disease:
336 usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis.
337 2008;47(5):659-667. [https://doi:10.1086/590559](https://doi.org/10.1086/590559)
- 338
339 13. Renesto P, Crapoulet N, Ogata H, et al. Genome-based design of a cell-free culture
340 medium for *Tropheryma whippelii*. Lancet. 2003;362(9382):447-449.
341 [https://doi:10.1016/S0140-6736\(03\)14071-8](https://doi.org/10.1016/S0140-6736(03)14071-8)
- 342
343 14. Empson MB. Statistics in the pathology laboratory: Characteristics of diagnostic tests,
344 Pathology 2001; 33:1, 93-95. [https://doi: 10.1080/00313020120034966](https://doi.org/10.1080/00313020120034966)
- 345
346 15. Receiver-Operator-Characteristic was performed using GraphPad Prism version 8.0.0 for
347 Windows, GraphPad Software, San Diego, California USA, www.graphpad.com".
- 348
349 16. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
350 [https://doi:10.1002/1097-0142\(1950\)3:1<32::aid-cncr2820030106>3.0.co;2-3](https://doi.org/10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3).
- 351
352 17. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size
353 estimation for diagnostic test studies. J Clin Epidemiol. 1991;44(8):763-770.
354 [https://doi:10.1016/0895-4356\(91\)90128-v](https://doi.org/10.1016/0895-4356(91)90128-v)

355

- 356 18. Black-Schaffer B. The Tinctoral Demonstration of a Glycoprotein in Whipple's
357 Disease. Proceedings of the Society for Experimental Biology and Medicine.
358 1949;72(1):225-227. [https://doi:10.3181/00379727-72-17388](https://doi.org/10.3181/00379727-72-17388)
359
- 360 19. Marth T, Strober W. Whipple's disease. Semin Gastrointest Dis 1996; 7:41-8.
361
- 362 20. Raoult D, Birg ML, La Scola B, et al. Cultivation of the bacillus of Whipple's disease
363 [published correction appears in N Engl J Med 2000 May 18;342(20):1538]. N Engl J
364 Med. 2000;342(9):620-625. [https://doi:10.1056/NEJM200003023420903](https://doi.org/10.1056/NEJM200003023420903)
365
- 366 21. Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T. Immunosuppressive
367 therapy in Whipple's disease patients is associated with the appearance of
368 gastrointestinal manifestations. Am J Gastroenterol. 2005;100(5):1167-1173.
369 [https://doi:10.1111/j.1572-0241.2005.40128.x](https://doi.org/10.1111/j.1572-0241.2005.40128.x)
370
- 371 22. Bonhomme CJ, Renesto P, Nandi S, Lynn AM, Raoult D. Serological microarray for a
372 paradoxical diagnostic of Whipple's disease. Eur J Clin Microbiol Infect Dis. 2008;
373 27(10):959-968. [https://doi:10.1007/s10096-008-0528-0](https://doi.org/10.1007/s10096-008-0528-0)
374
- 375 23. Carroll KC, Pfaller MA, Landry ML, et al. (ed). 2019. Manual of clinical
376 microbiology, 12th ed. ASM Press, Washington, DC.
377

- 378 24. Bonhomme CJ, Renesto P, Desnues B, et al. *Tropheryma whipplei* glycosylation in the
379 pathophysiologic profile of Whipple's disease. *J Infect Dis.* 2009;199(7):1043-1052.
380 [https://doi:10.1086/597277](https://doi.org/10.1086/597277)
381
- 382 25. Martinetti M, Biagi F, Badulli C, et al. The HLA alleles DRB1*13 and DQB1*06 are
383 associated to Whipple's disease. *Gastroenterology.* 2009; 136 (7):2289-2294.
384 [https://doi:10.1053/j.gastro.2009.01.051](https://doi.org/10.1053/j.gastro.2009.01.051).
385
- 386 26. Biagi F, Schiepatti A, Badulli C, et al. -295 T-to-C promoter region IL-16 gene
387 polymorphism is associated with Whipple's disease. *Eur J Clin Microbiol Infect Dis.*
388 2015;34(9):1919-1921. [https://doi:10.1007/s10096-015-2433-7](https://doi.org/10.1007/s10096-015-2433-7)
389
- 390 27. Biagi F, Badulli C, Feurle GE, et al. Cytokine genetic profile in Whipple's disease. *Eur J*
391 *Clin Microbiol Infect Dis.* 2012;31(11):3145-3150. [https://doi:10.1007/s10096-012-](https://doi.org/10.1007/s10096-012-1677-8)
392 [1677-8](https://doi.org/10.1007/s10096-012-1677-8)
393
- 394 28. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured
395 bacillus of Whipple's disease. *N Engl J Med.* 1992;327(5):293-301.
396 [https://doi:10.1056/NEJM199207303270501](https://doi.org/10.1056/NEJM199207303270501)
397
- 398 29. Moter A, Janneck M, Wolters M, et al. Potential Role for Urine Polymerase Chain
399 Reaction in the Diagnosis of Whipple's Disease. *Clin Infect Dis.* 2019;68(7):1089-1097.
400 [https://doi:10.1093/cid/ciy664](https://doi.org/10.1093/cid/ciy664)
401

- 402 30. Morgenegg S, Dutly F, Altwegg M. Cloning and sequencing of a part of the heat shock
403 protein 65 gene (hsp65) of "*Tropheryma whippelii*" and its use for detection of "*T.*
404 *whippelii*" in clinical specimens by PCR [published correction appears in J Clin
405 Microbiol 2000 Oct;38(10):3914]. J Clin Microbiol. 2000;38(6):2248-2253.
- 406
- 407 31. Fenollar F, Trani M, Davoust B, et al. Prevalence of asymptomatic *Tropheryma whipplei*
408 carriage among humans and nonhuman primates. J Infect Dis. 2008;197(6):880-887.
409 [https://doi:10.1086/528693](https://doi.org/10.1086/528693)
- 410
- 411 32. Schöniger-Hekele M, Petermann D, Weber B, Müller C. *Tropheryma whipplei* in the
412 environment: survey of sewage plant influxes and sewage plant workers. Appl Environ
413 Microbiol. 2007;73(6):2033-2035. [https://doi:10.1128/AEM.02335-06](https://doi.org/10.1128/AEM.02335-06)
- 414
- 415 33. Maiwald M, Schuhmacher F, Ditton HJ, von Herbay A. Environmental occurrence of the
416 Whipple's disease bacterium (*Tropheryma whippelii*). Appl Environ Microbiol.
417 1998;64(2):760-762. [https://doi:10.1128/AEM.64.2.760-762.1998](https://doi.org/10.1128/AEM.64.2.760-762.1998)
- 418
- 419 34. Marth T, Raoult D. Whipple's disease. Lancet. 2003;361(9353):239-246.
420 [https://doi:10.1016/S0140-6736\(03\)12274-X](https://doi.org/10.1016/S0140-6736(03)12274-X)
- 421
- 422 35. Keita AK, Dubot-Pérès A, Phommasone K, et al. High prevalence of *Tropheryma*
423 *whipplei* in Lao kindergarten children. PLoS Negl Trop Dis. 2015;9(2):e0003538.
424 Published 2015 Feb 20. [https://doi:10.1371/journal.pntd.0003538](https://doi.org/10.1371/journal.pntd.0003538)

425

426 36. Fenollar F, Trani M, Davoust B, et al. Prevalence of asymptomatic *Tropheryma whipplei*

427 carriage among humans and nonhuman primates. J Infect Dis. 2008;197(6):880-887.

428 <https://doi:10.1086/528693>

TABLE 1: Whipple’s Disease patients’ indirect immunofluorescence assay antibody titers.

Study patients	Gender	Age Range	IgM	IgG	IgA
Patient 1	M	71-75	256	128	<32
Patient 2	M	46-50	256	<8	<32
Patient 3	M	51-55	1024	16	32
Patient 4	M	36-40	256	32	<32
Patient 5	M	66-70	<32	<8	<32
Patient 6	M	56-60	256	<8	<32
Patient 7	M	56-60	128	<8	<32
Patient 8	M	71-75	<32	<8	<32
Patient 9	M	56-60	<32	<8	<32
Patient 10	F	66-70	512	16	<32
Patient 11	M	36-40	128	32	<32
Patient 12	M	36-40	256	256	<32
Patient 13	M	71-75	128	4096	128
Patient 14	M	81-85	<32	64	<32

TABLE 2: Indirect immunofluorescence assay antibody titers for healthy controls

Healthy Controls	Gender	Age Range	IgM	IgG	IgA
Control 1	F	56-60	64	256	<32
Control 2	F	41-45	128	256	<32
Control 3	F	41-45	64	256	<32
Control 4	F	36-40	128	128	32
Control 5	F	41-45	32	32	<32
Control 6	F	46-50	64	512	128
Control 7	F	46-50	256	256	<32
Control 8	M	51-55	64	256	<32
Control 9	F	26-30	512	64	256
Control 10	F	41-45	32	512	32
Control 11	F	31-35	<32	2048	<32
Control 12	F	31-35	512	256	<32
Control 13	F	36-40	128	512	<32
Control 14	M	36-40	<32	256	<32
Control 15	M	71-75	<32	512	<32
Control 16	F	21-25	128	32	32
Control 17	M	21-25	128	32	<32
Control 18	M	26-30	<32	256	<32
Control 19	M	36-40	<32	128	32
Control 20	F	41-45	128	32	<32

Control 21	F	21-25	<32	256	<32
Control 22	F	50-55	<32	512	<32

TABLE 3: Serological comparison of IgG antibody titers in Whipple’s Disease (WD)

patients and healthy controls; role in excluding WD in patients.

Antibody Titers	Whipple’s Disease	Healthy Controls	Sensitivity & Specificity	p-value[@]
IgG <256 (Test +)	12	7	Sn: 86% (95% CI 57-98%) Sp: 68% (95% CI 45-86%)	0.0022
IgG ≥ 256 (Test -)	2	15		
IgG < 128 (Test +)	11	5	Sn: 79% (95% CI 49-95%) Sp: 77% (95% CI 55-92%)	0.0017
IgG ≥ 128 (Test -)	3	17		
IgG < 64 (Test +)	10	4	Sn: 71% (95% CI 42-92%) Sp: 82% (95% CI 60-95%)	0.004
IgG ≥ 64 (Test -)	4	18		
IgG < 32 (Test +)	8	0	Sn: 57% (95% CI 29-82%) Sp: 100% (95% CI 85-100%)	0.0001
IgG ≥ 32 (Test -)	6	22		

IgG < 16 (Test +)	6	0	Sn: 43% (95% CI 18-71%) Sp: 100% (95% CI 85-100%)	0.0015
IgG ≥ 16 (Test -)	8	22		


[@] p-values are determined by Fisher's exact probability test; Sn: Sensitivity; Sp: Specificity

TABLE 4: Serological comparison of Whipple's Disease patients and healthy controls at an IgM antibody titer of ≥ 256

Antibody Titers	Whipple's Disease	Healthy Controls	Sensitivity & Specificity	p-value[@]
IgM ≥ 256 (Test +)	7	3	Sn: 50% (95% CI 23-77%)	0.03
IgM < 256 (Test -)	7	19	Sp: 86% (95% CI 65-97%)	

[@] p-values are determined by Fisher's exact probability test; Sn: Sensitivity; Sp: Specificity

FIG 1: Comparison of IgG antibody titers in Whipple’s Disease patients and healthy controls: ROC




Cut-offs	Sensitivity%	95% CI	Specificity %	95% CI	#Youden’s Index	[§] Likelihood ratio
$t_1 < 32$	57	29-82	100	85-100	0.57	Infinity
$t_2 < 64$	71	42-92	82	60-95	0.53	3.93
$t_3 < 128$	79	49-95	77	55-92	0.56	3.46
$t_4 < 256$	86	57-98	68	45-86	0.54	2.69
$t_5 < 512$	93	66-100	27	13-48	0.2	1.28
$t_6 < 1024$	93	66-100	4.5	0.2-22	-0.02	0.97

[#]Youden’s index represents a summary measurement of the ROC for the accuracy of a diagnostic test with ordinal or continuous endpoints.

[§]Likelihood ratio is basically a ratio of the probability that a test result is correct to the probability that the test result is incorrect.

FIG 2: Comparison of IgM antibody titers in Whipple’s Disease patients and healthy control:

ROC



Cut-offs	Sensitivity%	95% CI	Specificity %	95% CI	#Youden's Index	[§] Likelihood ratio
$t_1 \geq 32$	71	45-88	31	16-53	0.02	1.05
$t_2 \geq 64$	71	45-88	41	23-61	0.12	1.21
$t_3 \geq 128$	71	45-88	59	39-77	0.30	1.75
$t_4 \geq 256$	50	27-73	86	67-95	0.36	3.67
$t_5 \geq 512$	14	3-40	91	72-98	0.05	1.57
$t_6 \geq 1024$	7	0.4-31	100	85-100	0.07	Infinity

#Youden’s index represents a summary measurement of the ROC for the accuracy of a diagnostic test with ordinal or continuous endpoints.

[§]Likelihood ratio is basically a ratio of the probability that a test result is correct to the probability that the test result is incorrect.

FIG 3: Strategy for Diagnosis and Ruling out Whipple's Disease Using *Tropheryma*

whipplei Indirect Immunofluorescence Assay (IFA)

